Sanofi (NASDAQ:SNY) Shares Purchased by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. boosted its stake in Sanofi (NASDAQ:SNY) by 22.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 155,380 shares of the company’s stock after acquiring an additional 28,569 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Sanofi were worth $8,617,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Lee Danner & Bass Inc. acquired a new stake in Sanofi during the 4th quarter worth $31,000. Bessemer Group Inc. boosted its stake in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after purchasing an additional 242 shares during the last quarter. UMB Bank n.a. boosted its stake in Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock worth $62,000 after purchasing an additional 264 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in Sanofi during the 4th quarter worth $76,000. Finally, AdvisorNet Financial Inc boosted its stake in Sanofi by 16.4% during the 1st quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company’s stock worth $89,000 after purchasing an additional 227 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $48.18 on Tuesday. The business has a 50-day simple moving average of $51.16 and a 200-day simple moving average of $52.05. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The company has a market cap of $118.16 billion, a PE ratio of 17.21, a P/E/G ratio of 0.98 and a beta of 0.50. Sanofi has a one year low of $45.80 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.78 earnings per share. On average, equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were issued a $2.0369 dividend. This represents a yield of 3.1%. This is an increase from Sanofi’s previous annual dividend of $1.48. The ex-dividend date of this dividend was Friday, May 9th. Sanofi’s dividend payout ratio is 57.14%.

Analysts Set New Price Targets

SNY has been the topic of several analyst reports. Guggenheim reiterated a “buy” rating on shares of Sanofi in a report on Tuesday, June 3rd. The Goldman Sachs Group initiated coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target on the stock. BNP Paribas initiated coverage on Sanofi in a report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price target on the stock. Morgan Stanley set a $56.00 price target on Sanofi in a report on Monday, June 2nd. Finally, Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.